

Haematologica
HAEMATOL/2018/199364
Version 3

Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia

Salih Demir, Elena Boldrin, Qian Sun, Stephanie Hampp, Eugen Tausch, Cornelia Eckert, Martin Ebinger, Rupert Handgretinger, Geetruy te Kronnie, Lisa Wiesmüller, Stephan Stilgenbauer, Galina Selivanova, Klaus-Michael Debatin, and Lüder Hinrich Meyer

Disclosures: The authors would like to thank Aprea Therapeutics (Stockholm, Sweden) for kindly providing APR-246 for the study, S. Volk and S. Essig for excellent technical assistance, the Ulm University Sorting and Animal Facilities and Pharmacy of the Ulm University Medical Center, and the INFORM study group. The authors would also like to thank the International Graduate School in Molecular Medicine Ulm (SD, EB), Madeleine-Schickedanz-Stiftung and “Förderverein für Krebskranke Kinder Tübingen” (ME, RH), Swedish Research Council and Swedish Childhood Cancer Society (GS), EU COST Action CA16223 (GtK), German Research Foundation, SFB 1074 B6 (LHM, KMD) and B1 (SS) for supporting the work. GS is a co-founder and shareholder of Aprea Therapeutics, a company developing p53-based cancer therapy including APR-246. All other authors declare that no conflicts of interest exist.

Contributions: SD, EB, QS, SH, ET, CE, GtK, LW, SS, GS, KMD and LHM performed research, analyzed and interpreted data; CE, ME, RH and GtK provided samples and clinical information; SD and LHM designed research, SD prepared figures and tables, LHM wrote the manuscript; all authors read and approved the manuscript.